Analysts have been eager to weigh in on the Healthcare sector with new ratings on Spero Therapeutics (SPRO) and BioLife Solutions (BLFS).
Spero Therapeutics (SPRO)
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Spero Therapeutics yesterday and set a price target of $19.00. The company’s shares closed last Thursday at $13.89, close to its 52-week high of $14.94.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 28.3% and a 50.8% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spero Therapeutics with a $24.00 average price target.
See today’s analyst top recommended stocks >>
BioLife Solutions (BLFS)
Oppenheimer analyst Suraj Kalia maintained a Hold rating on BioLife Solutions yesterday. The company’s shares closed last Thursday at $31.39, close to its 52-week high of $32.72.
According to TipRanks.com, Kalia is a 3-star analyst with an average return of 2.5% and a 51.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioLife Solutions with a $34.10 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
